Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTI-01 in Infected, Non-draining Pleural Effusions
NCT04159831Phase 2Completed
- Sponsor
- Rein Therapeutics
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of urokinase plasminogen activator (LTI-01) (4 arms), sponsored by Rein Therapeutics. Primary endpoint: Incidence of referral to surgery. Started Sep 2020; status: completed.
02
Drugs
urokinase plasminogen activator (LTI-01)
Beyond the preview
Go deeper on NCT04159831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159831.